Don’t miss – Page 159 – Endpoints News

SIGN UP

After 2 delays, Zogenix nabs FDA approval for epilepsy drug, sets price at 3X its GW Pharma competitor

3 years ago

AbbVie’s first post-merger Allergan drug pitch strikes out with the FDA as regulators turn thumbs down on Lucentis challenger

3 years ago

Relay and iTeos join IPO deluge while Akouos and Fusion decide they can earn more

3 years ago

Over a decade ago, a disastrous trial killed research on a potential immunotherapy. Can a Regeneron bispecific revive it?

3 years ago

Sangamo splits the R from the D in a reorganization — and bids chief farewell

3 years ago

In an unexpected twist, CSL buys worldwide rights to uniQure's PhIII hemophilia B gene therapy in $2B-plus deal

3 years ago

Acceleron promised they had great data on sotatercept in late January. But was it good enough to justify a doubling of the stock price?

3 years ago

Is it really over? La Jolla signs acquisition with Tetraphase after outbidding AcelRx, Melinta

3 years ago

Burned by Alzheimer’s failures, a cautious Merck turns to a startup biotech for some preclinical neuro programs

3 years ago

UK Supreme Court strikes down Regeneron patents, opening door for Kymab

3 years ago

With its campus expanding as gene therapy booms, Aldevron brings in a top exec from a medtech giant to steer the course

3 years ago

Myovant readies NDA #3 as relugolix sails to its 5th positive PhIII — this time in endometriosis

3 years ago

Daniel O’Day snatches another I/O company, buying half of a pioneering cancer drug discoverer's biotech

3 years ago

Sanofi wants to earn the rep for being the hare in drug R&D. But that darn tortoise keeps sticking its head out

3 years ago

Sanofi bets $425M cash on a transformation-style next-gen vaccine deal — as the Big Pharma team makes a point

3 years ago

Roche’s anti-TIGIT drug shows zero response as monotherapy — but data back effect for lung cancer subset

3 years ago

Merck advances along a broad PhIII front, aimed at carving up Pfizer’s top-selling vaccine franchise. Could an ambush lay in wait?

3 years ago

Cell and gene therapy 2.0 dominates latest round of biotech IPOs in scramble for a $300M-plus Nasdaq windfall

3 years ago

Covid-19 roundup: In fifth open letter, Daniel O’Day touts inhalant remdesivir, promises 2M doses by year's end; Merck’s antiviral moves into PhII

3 years ago

Prominent Harvard professor in the hunt for $100M to back his anti-aging play

3 years ago

AbbVie sweeps out experimental gastro drugs in a post-merger pipeline cleanup. And they can likely be yours for the right price

3 years ago

Covid-19 roundup: One Chinese biotech enters clinic, another eyes fall completion, a third shoots for 2021 — while the Warp Speed general remains Sino-skeptic

3 years ago

'A turning point for the field': 4 years after Seres failure, Finch posts positive microbiome data

3 years ago

One of Roche’s spotlight PhIII cancer drug hopefuls stumbles in a key trial, with hit-and-miss results

3 years ago

First page Previous page 156 157 158159160 161 162 Next page Last page